Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer

被引：6

作者：

Henderson, Emily A. ^{[1
]}

Lukomski, Slawomir ^{[1
,2
]}

Boone, Brian A. ^{[1
,2
,3
]}

机构：

[1] West Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA

[2] West Virginia Univ, West Virginia Canc Inst, Morgantown, WV 26506 USA

[3] West Virginia Univ, Dept Surg, Morgantown, WV 26506 USA

来源：

FRONTIERS IN ONCOLOGY | 2023年 / 13卷

关键词：

bacterial therapy; pancreatic ductal adenocarcinoma; immunotherapy; anti-tumor immunity; bioengineering; GROUP-A STREPTOCOCCUS; BACILLUS-CALMETTE-GUERIN; METASTATIC BREAST-CANCER; COLLAGEN-LIKE PROTEIN-1; CLOSTRIDIUM-NOVYI-NT; SALMONELLA-TYPHIMURIUM; LISTERIA-MONOCYTOGENES; CELLULAR FIBRONECTIN; BCG IMMUNOTHERAPY; TUMOR;

D O I：

10.3389/fonc.2023.1217095

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic cancer is a highly aggressive form of cancer with a five-year survival rate of only ten percent. Pancreatic ductal adenocarcinoma (PDAC) accounts for ninety percent of those cases. PDAC is associated with a dense stroma that confers resistance to current treatment modalities. Increasing resistance to cancer treatments poses a challenge and a need for alternative therapies. Bacterial mediated cancer therapies were proposed in the late 1800s by Dr. William Coley when he injected osteosarcoma patients with live streptococci or a fabrication of heat-killed Streptococcus pyogenes and Serratia marcescens known as Coley's toxin. Since then, several bacteria have gained recognition for possible roles in potentiating treatment response, enhancing anti-tumor immunity, and alleviating adverse effects to standard treatment options. This review highlights key bacterial mechanisms and structures that promote anti-tumor immunity, challenges and risks associated with bacterial mediated cancer therapies, and applications and opportunities for use in PDAC management.

引用

页数：15

共 124 条

[1]

Aduro Biotech Inc, 2018, A phase 2B, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine (With cyclophosphamide) and CRS 207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma

[2]

Aduro Biotech Inc, 2018, A phase 2, randomized, multicenter, open-label study of the efficacy and immune response of the sequential administration of GVAX pancreas vaccine alone or followed by CRS-207 in adults with metastatic pancreatic adenocarcinoma

[3]

AstraZeneca, 2019, A phase Ib and II open-label, multi-center study of MEDI4736 evaluated in different combinations in patients with metastatic pancreatic ductal adenocarcinoma

[4]

Australasian Gastro-Intestinal Trials Group, 2022, Capecitabine ON temozolomide radionuclide therapy octreotate lutetium-177 NeuroEndocrine tumours study

[5]

Babaian KN., 2022, Bacillus calmette-guerin immunotherapy for bladder cancer: overview of BCG immunotherapy, mechanism of action of BCG, contraindications to BCG

[6] Genomic analyses identify molecular subtypes of pancreatic cancer [J].

Bailey, Peter ;

Chang, David K. ;

Nones, Katia ;

Johns, Amber L. ;

Patch, Ann-Marie ;

Gingras, Marie-Claude ;

Miller, David K. ;

Christ, Angelika N. ;

Bruxner, Tim J. C. ;

Quinn, Michael C. ;

Nourse, Craig ;

Murtaugh, L. Charles ;

Harliwong, Ivon ;

Idrisoglu, Senel ;

Manning, Suzanne ;

Nourbakhsh, Ehsan ;

Wani, Shivangi ;

Fink, Lynn ;

Holmes, Oliver ;

Chin, Vencssa ;

Anderson, Matthew J. ;

Kazakoff, Stephen ;

Leonard, Conrad ;

Newell, Felicity ;

Waddell, Nick ;

Wood, Scott ;

Xu, Qinying ;

Wilson, Peter J. ;

Cloonan, Nicole ;

Kassahn, Karin S. ;

Taylor, Darrin ;

Quek, Kelly ;

Robertson, Alan ;

Pantano, Lorena ;

Mincarelli, Laura ;

Sanchez, Luis N. ;

Evers, Lisa ;

Wu, Jianmin ;

Pinese, Mark ;

Cowley, Mark J. ;

Jones, Marc D. ;

Colvin, Emily K. ;

Nagrial, Adnan M. ;

Humphrey, Emily S. ;

Chantrill, Lorraine A. ;

Mawson, Amanda ;

Humphris, Jeremy ;

Chou, Angela ;

Pajic, Marina ;

Scarlett, Christopher J. .

NATURE, 2016, 531 (7592) :47-+

[7] Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients [J].

Baruch, Erez N. ;

Youngster, Ilan ;

Ben-Betzalel, Guy ;

Ortenberg, Rona ;

Lahat, Adi ;

Katz, Lior ;

Adler, Katerina ;

Dick-Necula, Daniela ;

Raskin, Stephen ;

Bloch, Naamah ;

Rotin, Daniil ;

Anafi, Liat ;

Avivi, Camila ;

Melnichenko, Jenny ;

Steinberg-Silman, Yael ;

Mamtani, Ronac ;

Harati, Hagit ;

Asher, Nethanel ;

Shapira-Frommer, Ronnie ;

Brosh-Nissimov, Tal ;

Eshet, Yael ;

Ben-Simon, Shira ;

Ziv, Oren ;

Khan, Md Abdul Wadud ;

Amit, Moran ;

Ajami, Nadim J. ;

Barshack, Iris ;

Schachter, Jacob ;

Wargo, Jennifer A. ;

Koren, Omry ;

Markel, Gal ;

Boursi, Ben .

SCIENCE, 2021, 371 (6529) :602-+

[8] Role of urothelial cells in BCG immunotherapy for superficial bladder cancer [J].

Bevers, RFM ;

Kurth, KH ;

Schamhart, DHJ .

BRITISH JOURNAL OF CANCER, 2004, 91 (04) :607-612

[9] DNase expression allows the pathogen group A streptococcus to escape killing in neutrophil extracellular traps [J].

Buchanan, JT ;

Simpson, AJ ;

Aziz, RK ;

Liu, GY ;

Kristian, SA ;

Kotb, M ;

Feramisco, J ;

Nizet, V .

CURRENT BIOLOGY, 2006, 16 (04) :396-400

[10] Nanotechnology and pancreatic cancer management: State of the art and further perspectives [J].

Caputo, Damiano ;

Pozzi, Daniela ;

Farolfi, Tommaso ;

Passa, Roberto ;

Coppola, Roberto ;

Caracciolo, Giulio .

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 13 (04) :231-237

← 1 2 3 4 5 6 7 8 9 10 →